Novo Nordisk A/S
The study is testing zenagamtide in participants with type 2 diabetes. The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have type 2 diabetes. Participants will either get zenagamtide or semaglutide. Which treatment participants get is decided by chance. Zenagamtide is a new medicine that doctors cannot prescribe yet, but it has been tested in humans before.
Inclusion Criteria: * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 years or above at the time of signing the informed consent. * Diagnosed with type 2 diabetes (T2D) greater than or equal to (≥ )180 days before screening. * On stable daily dose(s) of metformin, SGLT2 (sodium-glucose cotransporter 2) inhibitor, or both (at effective or maximum tolerated dose as judged by the investigator) prior to screening. Exclusion Criteria: * Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate…
Zenagamtide will be administered subcutaneously once weekly.
Semaglutide will be administered subcutaneously once weekly.
Placebo volume-matched to zenagamtide will be administered subcutaneously once weekly.
Placebo volume-matched to semaglutide will be administered subcutaneously once weekly.